brexpiprazole (MTD211) / Biodexa Pharma - LARVOL DELTA

And Now, The FDA Approves A Medication For Behavioral Symptoms Of Alzheimer’s Disease (UCI MIND) - "Brexpiprazole has now been approved by the FDA for the treatment of agitation in Alzheimer's dementia. Agitated behaviors are common in those with moderate or advanced Alzheimer's dementia and these symptoms contribute substantially to caregiver burden...These trials also reflect some improvements in the quality of behavioral symptom trials, with careful inclusion criteria, valid measures of target symptoms, and convergent findings across several trials."

Online posting • Regulatory

Anatomy of an Industry: Commerce, Payments to Psychiatrists and Betrayal of the Public Good (Mad in America) - "Kane, Correll and the company employees concluded that this 'meta-analysis of the pivotal studies indicates brexpiprazole 2 mg and 4 mg are effective in treating acute schizophrenia.'"

Media quote • Psychiatry • Schizophrenia

Midatech Pharma Stock Jumps After Breakthrough Data On Encapsulation Of Biologic Using Q-Sphera (Yahoo Finance) - "Midatech Pharma PLC (NASDAQ: MTP) has announced a breakthrough in vitro data utilizing Q-Sphera technology and progress across multiple other programs....MTP shares are up 74% at $3.55 during the premarket trading session on the last check Thursday."

Preclinical • Stock price • CNS Disorders • Depression • Schizophrenia

Midatech Pharma PLC Announces Breakthrough Data Using Q-Sphera Technology (BioSpace) - "Midatech Pharma PLC...announces breakthrough in vitro data which demonstrate Q-Sphera's potential to formulate proteins into long-acting injectable products, as well as significant progress across multiple other programmes....As part of its internal pipeline, the Company has successfully developed a long-acting formulation of brexpiprazole. In in vivo studies, MTD211 was well tolerated and demonstrated that a single dose of MTD211 is expected to deliver therapeutic blood levels of brexpiprazole over a period of three months....The Company has initiated discussions with third parties about a potential licencing of MTD211."

Preclinical • CNS Disorders • Depression • Schizophrenia